Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2
0HD2 Stock Chart & Stats
Day’s Range― - ―
52-Week Range$142.05 - $303.89
Previous CloseN/A
Volume1.06K
Average Volume (3M)514.00
Market Cap
$30.17B
Enterprise Value$35.31B
Total Cash (Recent Filing)$966.43M
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta0.47
Next Earnings
May 01, 2025EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding129,457,150
10 Day Avg. Volume623
30 Day Avg. Volume514
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.08
Price to Cash Flow (P/CF)-83.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit18.35
Enterprise Value/Ebitda-182.95
Forecast
1Y Price Target
$325.18Price Target Upside36.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
---
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionAlnylam is cementing its leadership in the space, targeting market expansion well into the 2040s with a franchise that could generate peak annual revenues of $20B-plus, if approved.
Therapeutic AdvancementsNucresiran could increase Alnylam net revenues by up to $1-2B/year, enhancing competitiveness in ATTR-CM.
Bears Say
Approval TimelinesALNY’s aspiration for 2030 approval seems aggressive to us.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.38% Insiders
49.21% Mutual Funds
0.20% Other Institutional Investors
35.01% Public Companies and Individual Investors
0HD2 FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest share price was $142.05 and its highest was $303.89 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $30.17B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is May 01, 2025 which is in 50 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Feb 13, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.592 by -$0.058.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -0.95.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 129,457,150 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.592. Following the earnings report the stock price went down -0.178%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0HD2
---
Alnylam Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$325.18 (36.57% Upside)
$325.18 (36.57% Upside)
Blogger Sentiment
Bullish
GB:0HD2 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
55.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.32%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
---
0HD2 Company Deck
---
0HD2 Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant revenue growth, profitability, and progress in clinical trials. Despite a slight decline in the rare franchise and anticipated decrease in gross margins, the strong performance and guidance in key areas like the TTR franchise and R&D pipeline suggest a positive outlook.Read More>---
0HD2 Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
---
0HD2 Stock 12 Month Forecast
Average Price Target
$325.18
▲(36.57% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Biogen
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering 0HD2
1 Year
1 Year Success Rate
26/37 ratings generated profit
1 Year Average Return
+26.03%
reiterated a buy rating 4 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 70.27% of your transactions generating a profit, with an average return of +26.03% per trade.
---